JAM
TAK icon

JCIC Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

JCIC Asset Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-146,710
Closed -$2.62M – 126
2020
Q3 		$2.62M Buy
+146,710
New +$2.67M 1.21% 31

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

JCIC Asset Management's TAK Position: Q4 2020 in Review

JCIC Asset Management sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 146,710 shares — an estimated $2.62M sold.

JCIC Asset Management first reported a position in TAK in Q3 2020 and held it in 1 quarter. The position peaked at $2.62M in Q3 2020. 312 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • JCIC Asset Management reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • JCIC Asset Management sold 146,710 Takeda Pharmaceutical shares in Q4 2020, an estimated $2.62M.
  • JCIC Asset Management first reported a position in Takeda Pharmaceutical in Q3 2020 and held it in 1 quarter.
  • JCIC Asset Management's Takeda Pharmaceutical position peaked at $2.62M in Q3 2020.
  • 312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on JCIC Asset Management's 13F filing for Q4 2020, filed 23 Feb 2021.